CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here are 6 more biotechs shaping CRISPR landscape
The market potential of CRISPR technology has been legitimized by Editas Medicine's impressive, $120 million fundraise. Here are six more biotechs shaping the CRISPR landscape look like now? And what other players are in this game?